Skip to main content

Advertisement

Table 5 Adjusted effect of amitriptyline, duloxetine, and gabapentin, compared to pregabalin, on health care utilization in patients with treatment duration of at least 180 days a

From: Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia

Health care utilization Amitriptyline, RR (95% CI) b Duloxetine, RR (95% CI) b Gabapentin, RR (95% CI) b
Outpatient visitsc 0.91 (0.84 to 0.99)* 0.94 (0.88 to 1.00)* 0.94 (0.88 to 1.00)*
PCP visitsc 0.99 (0.90 to 1.09) 0.92 (0.85 to 0.98)* 0.92 (0.85 to 0.98)*
Any specialist visitsc 0.85 (0.77 to 0.95)* 0.89 (0.82 to 0.97)* 0.89 (0.82 to 0.97)*
Prescription drugsc 0.97 (0.91 to 1.03) 0.94 (0.90 to 0.98)* 0.94 (0.90 to 0.98)*
Acute hospitalizationd 0.63 (0.41 to 0.95)* 0.76 (0.57 to 1.01) 0.73 (0.59 to 0.90)*
ED visitsc 1.07 (0.84 to 1.37) 1.00 (0.83 to 1.19) 1.03 (0.90 to 1.17)
Physical therapyd 0.76 (0.55 to 1.06) 0.85 (0.67 to 1.09) 0.99 (0.82 to 1.19)
  1. aCI, Confidence interval; ED, Emergency department; PCP, Primary care physician; RR, Rate ratio. bPregabalin was used as the reference group. cMultivariable Poisson regression was used. dMultivariable Cox proportional hazards regression was used. *Statistically significant difference (P < 0.05). All rate ratios were adjusted for neuropathic pain and the number of outpatient visits, PCP visits, any specialist visits, prescription drugs, acute hospitalizations, and ED visits at baseline.